National Institute Of Mental Health And Neuro Sciences

National Institute Of Mental Health And Neuro Sciences, a foreign-owned non-profit educational institution headquartered in Bengaluru, India, operates as a federal grant recipient and subrecipient on NIH-funded research programs focused on neuropsychiatric and neurodegenerative disease phenotyping, genetic profiling, and digital mental health interventions in India. The institute participates predominantly (86%) as a subrecipient on NIH grants issued to domestic academic primes, with a single recent prime grant from the National Institute on Aging.

The institute's federal footprint centers on the National Institutes of Health. Six awards route through the National Institute of Mental Health, five through the National Institute on Aging, and one each through the National Cancer Institute and the Fogarty International Center; the Centers for Disease Control and Prevention issued one award. All identified customer agencies fall within the Department of Health and Human Services. The organization has received $9.4 million in combined federal dollars across fourteen awards spanning 2013 through September 2026, with the most recent activity concentrated in 2024–2025 (eleven of the fourteen awards).

As a grant recipient, the National Institute Of Mental Health And Neuro Sciences received a $215,961 Aging Research program grant (CFDA 93.866) from the National Institute on Aging dated September 1, 2026, running through August 31, 2028. The award establishes and characterizes a 300-member cohort of presymptomatic family members of frontotemporal dementia patients in India through deep phenotyping, genetic profiling, serum biomarkers, and advanced brain imaging, with work performed in India targeting early indicators of disease progression in carriers of C9ORF72, GRN, and MAPT mutations.

As a subrecipient, NIMHANS participates on NIH grants led by The Broad Institute (three sub-awards on the Asian Bipolar Genetics Network, A-BIG-Net), Emory University (two awards), University of California San Francisco (two awards), Harvard College (one award on schizophrenia care integration in India), University of California Irvine (one award), University of Melbourne (one award on the PRESCIENT study), and University of Maryland Baltimore (one award on disability benefit outcomes in first episode psychosis). The institute's sub-award work involves recruitment, participant monitoring, cognitive and language assessment, biomarker and imaging data collection, study protocol implementation, institutional ethics review submissions, and field supervision of research staff in Bengaluru and rural Karnataka and Madhya Pradesh.

Activity grew substantially in 2024–2025 after a sparse period (five awards in 2024, six in 2025) but receded to one award in 2026. One award reaches ultimate completion within the next twenty-four months, posing minimal recompete exposure. The institute functions as a India-based research site and enrollment center for U.S.-led neuroscience and psychiatry research, leveraging its clinical infrastructure and population diversity for federally funded studies underrepresented in Western research cohorts.